Syndax Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Syndax Pharmaceuticals generated cash of -$160,601,000, which is less than the previous year. Cash used in financing activities reached the amount of $264,132,000 last year. Net change in cash is therefore $221,140,000.
Cash Flow
| 2014 | -14.39M | 1.88M | 12.41M |
|---|---|---|---|
| 2015 | -2.42M | -61.66M | 77.26M |
| 2016 | -35.15M | -18.38M | 54.20M |
| 2017 | -47.37M | -17.02M | 75.72M |
| 2018 | -68.53M | 51.39M | 15.72M |
| 2019 | -50.61M | 12.78M | 28.57M |
| 2020 | -71.26M | -142.53M | 304.42M |
| 2021 | 29.13M | -40.87M | 118.46M |
| 2022 | -133.67M | -186.18M | 172.25M |
| 2023 | -160.60M | 117.60M | 264.13M |
SNDX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 74.47M | 222.08M | 115.35M | 24.72M | 33.98M | 35.38M | 23.84M | 23.17M | 10.00M | 10.10M |
Operating activities | ||||||||||
Net income | -209.36M | -149.33M | 24.92M | -73.15M | -56.04M | -73.96M | -60.80M | -44.47M | -24.11M | -19.82M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 12K | 33K | 43K | 89K | 92K | 78K | 76K | 89K | 21K | 15K |
Stock-based compensation expense | 30.95M | 16.01M | 13.31M | 9.05M | 6.00M | 6.20M | 5.45M | 4.70M | 3.88M | 2.25M |
| Deferred income tax benefit | 30.95M | 16.01M | 13.31M | 9.05M | 6.00M | 6.20M | 5.45M | 4.70M | 3.88M | 2.25M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | -3.47M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 3.47M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 5.61M | -1.31M | 2.16M | -2.67M | 4.73M | -792K | -194K | 923K | 1.04M | -726K |
Cash generated by operating activities | -160.60M | -133.67M | 29.13M | -71.26M | -50.61M | -68.53M | -47.37M | -35.15M | -2.42M | -14.39M |
Investing activities | ||||||||||
Purchases Of Investments | -354.60M | -495.34M | -294.71M | -278.93M | -104.01M | -78.84M | -152.26M | -158.31M | -102.00M | -3.39M |
Investments In Property Plant And Equipment | 0 | -225K | -129K | 0 | 0 | -187K | -84K | -261K | -49K | -4K |
Acquisitions Net | 0 | 225K | 40.74K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 117.60M | -186.18M | -40.87M | -142.53M | 12.78M | 51.39M | -17.02M | -18.38M | -61.66M | 1.88M |
Financing activities | ||||||||||
Common Stock Issued | 258.09M | 181.39M | 118.46M | 284.69M | 28.21M | 15.49M | 75.34M | 52.14M | 87.51M | 6K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -20.99M | 0 | -19.73M | 0 | 0 | 0 | 0 | -9M | -2K |
Cash used in financing activities | 264.13M | 172.25M | 118.46M | 304.42M | 28.57M | 15.72M | 75.72M | 54.20M | 77.26M | 12.41M |
Net Change In Cash | 221.14M | -147.60M | 106.72M | 90.63M | -9.26M | -1.40M | 11.32M | 665K | 13.17M | -95K |
Cash at end of period | 295.61M | 74.47M | 222.08M | 115.35M | 24.72M | 33.98M | 35.16M | 23.84M | 23.17M | 10.00M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |